We provide you with 20 years of free, institutional-grade data for DNLI stock, allowing you to gain comprehensive visibility into the fundamentals of the company. This in-depth information is essential for making informed investment decisions and understanding the financial health and performance of DNLI. Explore the full financial landscape of DNLI stock.
| Reported Date | CIK | Ticker | Type | |
|---|---|---|---|---|
| 2025-08-11 | 1714899 | DNLI | 10-Q | Url |
| 2025-05-06 | 1714899 | DNLI | 10-Q | Url |
| 2025-02-27 | 1714899 | DNLI | 10-K | Url |
| 2024-11-06 | 1714899 | DNLI | 10-Q | Url |
| 2024-08-01 | 1714899 | DNLI | 10-Q | Url |
| 2024-05-07 | 1714899 | DNLI | 10-Q | Url |
| 2024-02-28 | 1714899 | DNLI | 10-K | Url |
| 2023-11-07 | 1714899 | DNLI | 10-Q | Url |
| 2023-08-08 | 1714899 | DNLI | 10-Q | Url |
| 2023-05-08 | 1714899 | DNLI | 10-Q | Url |
| 2023-02-27 | 1714899 | DNLI | 10-K | Url |
| 2022-11-03 | 1714899 | DNLI | 10-Q | Url |
| 2022-08-08 | 1714899 | DNLI | 10-Q | Url |
| 2022-05-05 | 1714899 | DNLI | 10-Q | Url |
| 2022-02-28 | 1714899 | DNLI | 10-K | Url |
| 2021-11-04 | 1714899 | DNLI | 10-Q | Url |
| 2021-08-04 | 1714899 | DNLI | 10-Q | Url |
| 2021-05-05 | 1714899 | DNLI | 10-Q | Url |
| 2021-02-26 | 1714899 | DNLI | 10-K | Url |
| 2020-11-05 | 1714899 | DNLI | 10-Q | Url |
| 2020-08-07 | 1714899 | DNLI | 10-Q | Url |
| 2020-05-07 | 1714899 | DNLI | 10-Q | Url |
| 2020-02-27 | 1714899 | DNLI | 10-K | Url |
| 2019-11-06 | 1714899 | DNLI | 10-Q | Url |
| 2019-08-06 | 1714899 | DNLI | 10-Q | Url |
| 2019-05-08 | 1714899 | DNLI | 10-Q | Url |
| 2019-03-12 | 1714899 | DNLI | 10-K | Url |
| 2018-11-08 | 1714899 | DNLI | 10-Q | Url |
| 2018-08-09 | 1714899 | DNLI | 10-Q | Url |
| 2018-05-11 | 1714899 | DNLI | 10-Q | Url |
| 2018-03-19 | 1714899 | DNLI | 10-K | Url |
| 2017-11-13 | 1714899 | DNLI | S-1 | Url |
Denali Therapeutics Inc(NASDAQ:DNLI) 
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. The company offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidates, including DNL201 that has completed Phase 1b clinical trials...
Website: http://www.denalitherapeutics.com
Founded: 2013
Full Time Employees: 281
Sector: Healthcare
Industry: Biotechnology
The information provided in this report about DNLI stock is taken from www.sec.gov and many other data providers. While we have conducted our best efforts to ensure that the parsed data is accurate, we cannot guarantee its accuracy. Please use caution and understand that any consequences of its use are your own responsibility.